Is Lineage Cell Therapeutics stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
Yes, Lineage Cell Therapeutics pays dividends. Last time was Thursday 1st of January 1970 where the investors holding the stock on Monday 15th of December 2003 were paid $0.08 per share. Over the last 1 times between 2003 and 2003, Lineage Cell Therapeutics has paid $0.08 with an average of $0.08 per share.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Lineage Cell Therapeutics 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was $0.936, you would have made a loss of $-0.0995 per share or -10.64%
No, the average daily trading liquidity for Lineage Cell Therapeutics is $658 317 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Lineage Cell Therapeutics has no real debt, which is good in periods of high inflation. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Lineage Cell Therapeutics to be medium [0.7 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.